May 6, 2011
FERRING PHARMACEUTICALS TO SUPPORT GREAT PROSTATE CANCER CHALLENGE® EVENTS ACROSS THE COUNTRY IN NATIONAL EFFORT TO END PROSTATE CANCER
Ferring Named Official Sponsor of the Great Prostate Cancer Challenge
PARSIPPANY, NJ – May 6, 2011 – Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge®, the fastest growing men’s health event series in the United States. Now in its fifth year, the Great Prostate Cancer Challenge (GPCC) is led by ZERO – The Project to End Prostate Cancer.
“The Great Prostate Cancer Challenge is an inspiring example of communities coming together in an effort to stop prostate cancer, and to support all those who have been impacted by this disease,” said William Garbarini, Vice President, US Marketing, Ferring Pharmaceuticals Inc. “We are extremely proud to support this worthwhile event series, and we congratulate ZERO and all GPCC participants.”
ZERO expects more than 15,000 participants across 27 cities in this year’s Great Prostate Cancer Challenge events. Atlanta, Detroit, and Tucson are just a few of the cities where running races and walks will be held. This year’s first GPCC event will be held in Albuquerque, NM on Saturday, May 7. The widespread exposure generated by the GPCC events will go a long way toward advancing the organization’s mission—zero tolerance for prostate cancer.
The first GPCC event took place in 2007 in an effort to promote prostate cancer awareness, early detection and research. To date, the national event series has raised nearly $2 million. ZERO dedicates the proceeds from each event to free prostate cancer screenings in the host community.
“The ZERO team is excited to have Ferring as a partner for the Great Prostate Cancer Challenge,” said ZERO’s CEO Skip Lockwood. “Their product FIRMAGON is one important treatment option for patients with advanced prostate cancer. Their support of the GPCC demonstrates their commitment to the goal of helping end prostate cancer and those who are suffering from this disease.”
Prostate cancer is diagnosed approximately every two minutes, and takes about one life every 18 minutes. It is the most common non-skin cancer, and the second leading cause of cancer death in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of this disease.
To get information on a Great Prostate Cancer Challenge event in your area, visit: http://www.GreatProstateCancerChallenge.com/
About ZERO – The Project to End Prostate Cancer
Zero prostate cancer deaths. Zero prostate cancer cases and for those with prostate cancer, it means a zero PSA. The name stands for zero tolerance for prostate cancer. ZERO – The Project to End Prostate Cancer is committed to not only reducing prostate cancer and alleviating pain from the disease but to end it. They see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life, with the support they need to minimize physical and emotional suffering and to cope effectively throughout their cancer journeys. They provide comprehensive treatment information to patients, education to those at risk and conduct free prostate cancer testing throughout the country. They increase research funds from the federal government to find new treatments and fund local grants to end the disease.
FIRMAGON is a prescription medicine used in the treatment of advanced prostate cancer. Important Safety Information FIRMAGON should not be given to people who are allergic to any of the ingredients in FIRMAGON. It should not be given to women who are pregnant or may become pregnant. FIRMAGON can harm an unborn baby when given to a pregnant woman.
Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you have any heart problems, problems with balance of your body salts or electrolytes (such as, sodium, potassium, calcium, and magnesium), or have kidney or liver problems.
The common side effects of FIRMAGON include: hot flashes, injection site pain, redness and swelling (especially with the first dose), weight gain, increase in some liver enzymes, tiredness, hypertension, back and joint pain, chills, urinary tract infection, and decreased sex drive and trouble with erectile function (impotence). Please see Full Prescribing Information at www.Firmagon.com.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a Swiss-headquartered, research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, reproductive health and urology. Ferring Pharmaceuticals offers a line of urology, infertility, gynecology, and orthopaedic products in the U.S. market. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.